111 related articles for article (PubMed ID: 3040246)
1. Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer.
Conley BA; Hornedo J; Abrams J; Eisenberger M; Hiponia D; Aisner J; Van Echo DA
Cancer Treat Rep; 1987 Sep; 71(9):861-2. PubMed ID: 3040246
[No Abstract] [Full Text] [Related]
2. Phase II trial of esorubicin in patients with advanced non-small cell lung cancer.
Kris MG; Gralla RJ; Burke MT; Fiore JJ; Kelsen DP; Marks LD; Heelan RT
Cancer Treat Rep; 1987; 71(7-8):783-4. PubMed ID: 3038319
[No Abstract] [Full Text] [Related]
3. Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer.
Kaplan S; Sessa C; Joss R; Obrecht JP; Siegenthaler P; Cavalli F
Cancer Treat Rep; 1985 Nov; 69(11):1337-8. PubMed ID: 4092200
[No Abstract] [Full Text] [Related]
4. [New anthracycline analogues in the treatment of lung cancer].
Ueoka H; Ohnoshi T; Kimura I
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2146-9. PubMed ID: 1332624
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of deoxydoxorubicin in patients with advanced liver cancer.
Perry DJ; Van Echo DA; Mick R
Cancer Treat Rep; 1987 Nov; 71(11):1117-8. PubMed ID: 3119209
[No Abstract] [Full Text] [Related]
6. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
Myers JW; Von Hoff DD; Clark GM; Coltman CA
Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
[No Abstract] [Full Text] [Related]
7. Phase II trial of 4' deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study.
Rose C; Lad TE; Kilton LJ; Schor J; Rosen ST; Rossof AH; Blough RR; Johnson CM
Invest New Drugs; 1990 Feb; 8(1):97-9. PubMed ID: 2160920
[TBL] [Abstract][Full Text] [Related]
8. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
Feld R; Evans WK; Shepherd FA; Deboer G; Ottema B
Cancer Treat Rep; 1985 Feb; 69(2):209-10. PubMed ID: 3971392
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of esorubicin in patients with advanced colorectal carcinoma.
Fiore J; Kemeny N; Raymond V; Young C
Cancer Treat Rep; 1986 Oct; 70(10):1241-2. PubMed ID: 3530453
[No Abstract] [Full Text] [Related]
10. Bisantrene in non-small cell lung cancer: a phase II trial of the Cancer and Leukemia Group B.
Green MR; Vosika G; Propert KJ; Ware JH; Comis R
Cancer Treat Rep; 1986 Apr; 70(4):539-40. PubMed ID: 3698052
[No Abstract] [Full Text] [Related]
11. Phase II study of isotretinoin in the treatment of advanced non-small cell lung cancer.
Grunberg SM; Itri LM
Cancer Treat Rep; 1987 Nov; 71(11):1097-8. PubMed ID: 2824046
[No Abstract] [Full Text] [Related]
12. Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.
Kramer BS; Birch R; Gockerman JP; Greco A; Prestridge K
Cancer Treat Rep; 1986 Jun; 70(6):803-4. PubMed ID: 3015404
[No Abstract] [Full Text] [Related]
13. [Objective cytometric parameters for evaluating the grade of induced pathomorphosis of non-small-cell lung cancer].
Tuganova TN
Vopr Onkol; 2008; 54(5):631-5. PubMed ID: 19069480
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of caracemide in advanced or recurrent non-small cell lung cancer.
Belani CP; Eisenberger M; Van Echo D; Hiponia D; Aisner J
Cancer Treat Rep; 1987 Nov; 71(11):1099-100. PubMed ID: 2824047
[No Abstract] [Full Text] [Related]
15. Treatment of advanced non-small cell lung cancer with bisantrene.
Fuks JZ; Van Echo DA; Garbino C; Kasdorf H; Aisner J
Cancer Treat Rep; 1983 Jun; 67(6):597-8. PubMed ID: 6305499
[No Abstract] [Full Text] [Related]
16. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
[TBL] [Abstract][Full Text] [Related]
17. Phase II study on DON in patients with previously treated advanced lung cancer.
Eagan RT; Frytak S; Nichols WC; Creagan ET; Ingle JN
Cancer Treat Rep; 1982 Aug; 66(8):1665-6. PubMed ID: 6286122
[No Abstract] [Full Text] [Related]
18. Phase II trial of 4'-epi-doxorubicin in patients with non-small cell lung cancer.
Kalman LA; Kris MG; Gralla RJ; Kelsen DP; Casper ES; Heelan RT; Wittes RE
Cancer Treat Rep; 1983 Jun; 67(6):591-2. PubMed ID: 6574820
[No Abstract] [Full Text] [Related]
19. Phase II study of 5,6-dihydro-5-azacytidine in extensive, untreated non-small cell lung cancer.
Holoye PY; Dhingra HM; Umsawasdi T; Murphy WK; Carr DT; Lee JS
Cancer Treat Rep; 1987 Sep; 71(9):859-60. PubMed ID: 2441864
[No Abstract] [Full Text] [Related]
20. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
